Table 1 Correlation of demographic features and disease characteristics with response to NSAID monotherapy

Patients

13

38

36

 Male, n (%)

7 (54%)

15 (39%)

17 (47%)

0.71

0.52

 Age at presentation, mean (SD)

4.8 (3.6)

7.1 (4.7)

6.1 (4.6)

0.68

0.10*

 Age ≤ 8 years at presentation, n (%)

11 (85%)

21 (55%)

27 (75%)

0.23

0.10*

 Initial joint count, mean (SD)

1.8 (1.6)

5.7 (9.0)

4.7 (6.3)

0.98

0.01**

 Joint count ≤5, n (%)

13 (100%)

29 (76%)

29 (81%)

0.83

0.09*

 Characteristic rash, n (%)

13 (100%)

34 (89%)

33 (92%)

0.93

0.56

 Generalized lymphadenopathy, n (%)

2 (15%)

6 (16%)

9 (25%)

0.28

1.00

 Hepatosplenomegaly, n (%)

2 (15%)

7 (18%)

5 (14%)

0.64

1.00

 Serositis, n (%)

0 (0%)

1 (3%)

8 (22%)

0.003**

1.00

 CRP ≤13 mg/dL*, n (%)

12 (92%)

26 (68%)

17 (59%)

0.14*

0.14*

 MAS at diagnosis, n (%)

0 (0%)

2 (5%)

7 (19%)

0.03**

1.00

 MAS ever, n (%)

0 (0%)

6 (16%)

11 (31%)

0.03**

0.32

 WBC (K/μL), mean (SD)

16.7 (±7.0)

16.4 (±7.0)

19.6 (±10.1)

0.15

0.89

 Hg (g/dL), mean (SD)

10.4 (±0.9)

10.1 (±1.5)

9.9 (±1.6)

0.45

0.47

 Platelets (K/μL), mean (SD)

492 (±193)

486 (±222)

519 (±248)

0.57

0.93

 ESR (mm), mean (SD)

80 (±26)

77 (±26)

75 (±31)

0.69

0.81

 Ferritin (ng/mL), mean (SD)

410 (±722)

3042 (±4813)

3060 (±3777)

0.55

0.07*

 Days to clinically inactive disease, median (range)

49 (28-356)

764 (13-3806)

267 (0-2716)

0.60

0.0001**

 Days to medication escalation, median (range)

n/a

32 (2-146)

n/a

n/a

n/a

 Days to first follow-up, median (range)

48 (28-252)

21 (6-327)

27 (9-188)

0.33

0.004**

 Days of disease duration prior to diagnosis, median (range)

55 (26-492)

46 (14-484)

81 (11-848)

0.25

0.60

 Days of total follow-up, median (range)

1000 (154-3164)

1693 (0-4229)

956 (188-4678)

0.45

0.37